NET CONNECT has summarised highlights of the recent ASCO 2019 meeting for you. Neuroendocrine Tumour Update by Dr Aman Chauhan University of Kentucky’s Markey Cancer Center (NCI Designated Cancer Center), Kentucky, USA
NET CONNECT has summarised highlights of the recent ASCO 2019 meeting for you. Neuroendocrine Tumour Update by Dr Aman Chauhan University of Kentucky’s Markey Cancer Center (NCI Designated Cancer Center), Kentucky, USA
00:00:00
Results of ALLIANCE
Bergsland et al. Abstract #4005 ASCO 2019
00:03:51
Final results of TALENT
Capdevila et al. Abstract #4106 ASCO 2019
00:05:48
Results of DART
Patel et al. Abstract #CT039 AACR 2019
Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects.
His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee.
Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society.
Two emerging and two established targets
Announcing the publication of survey results
An expert overview of the EMERALD subgroup analysis
Managing patients with nccRCC: guidelines, recommendations, and best practice
Risk factors, diagnostic tools and treatment options for different patient groups
Exploring emerging treatment strategies presented at SABCS 2024